drugset / Trial / NCT02319941
Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes
Phase 2
Completed
65 enrolled
CardioVascular Research Foundation
AstraZeneca · collabKBM pharm · collabRoche Pharma AG · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients with Acute Coronary Syndromes
Timeline
- Start
- 2015-05-20
- Primary completion
- 2017-02-14
- Completion
- 2017-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Ticagrelor | Small molecule | 60 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |